Literature DB >> 26562579

Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.

William Makis1, Karey McCann, Alexander J B McEwan.   

Abstract

A 70-year-old woman presented with frequent episodes of hypoglycemia. Imaging revealed a 6-cm pancreatic mass with several liver lesions. The pancreatic mass was resected and confirmed to be a well-differentiated insulinoma. Surgery improved but did not resolve her hypoglycemic episodes, and she was referred for peptide receptor radionuclide therapy with 177Lu-DOTATATE to treat her residual disease. A modified protocol with a continuous IV dextrose infusion was used, and the treatments were well tolerated. After 4 induction and 2 maintenance treatments, her hypoglycemic symptoms resolved completely and her disease stabilized. She has been progression free for 24 months.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26562579     DOI: 10.1097/RLU.0000000000001023

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 2.  Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE.

Authors:  Shejil Kumar; Mariah Melek; Peter Rohl
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-24       Impact factor: 6.055

3.  LONG-TERM EFFECT OF 177LU-DOTATATE ON SEVERE AND REFRACTORY HYPOGLYCEMIA ASSOCIATED WITH MALIGNANT INSULINOMA.

Authors:  Pedro Iglesias; Alberto Martínez; Pablo Gajate; Teresa Alonso; Teresa Navarro; Juan J Díez
Journal:  AACE Clin Case Rep       Date:  2019-06-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.